 YONKERS, N.Y., May 03, 2021 GLOBE NEWSWIRE -- ContraFect Corporation Nasdaq: CFRX, a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 10,988,520 the 520 patent, on April 27, 2021 for CF-370, the companys second potential therapeutic product candidate. The 520 patent, which is owned by ContraFect, expires in March of 2039, and is the latest U.S. patent to issue from the companys DLA patent portfolio. 